THCCC | CAS#1259532-01-8 | glutamate receptor modulator

MedKoo Cat#: 563372 | Name: THCCC

Description:

WARNING: This product is for research use only, not for human or veterinary use.

THCCC is a dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulator and a PHCCC analog.

Chemical Structure

THCCC

CAS#1259532-01-8

Theoretical Analysis

MedKoo Cat#: 563372

Name: THCCC

CAS#: 1259532-01-8

Chemical Formula: C18H16N2O3

Exact Mass: 308.1161

Molecular Weight: 308.33

Elemental Analysis: C, 70.12; H, 5.23; N, 9.09; O, 15.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

THCCC;

IUPAC/Chemical Name

(7E)-7-Hydroxyimino-N-(4-methyl)phenyl-1,7a-dihydrocyclopropa[b]chromene-1a-carboxamide

InChi Key

VKCTUZKPBYSTDW-SILNSSARSA-N

InChi Code

InChI=1S/C18H16N2O3/c1-11-6-8-12(9-7-11)19-17(21)18-10-14(18)16(20-22)13-4-2-3-5-15(13)23-18/h2-9,14,22H,10H2,1H3,(H,19,21)/b20-16-

SMILES Code

O=C(C1(C2)C2/C(C3=C(O1)C=CC=C3)=N\O)NC4=CC=C(C)C=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 308.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Rabin KR, Poplack DG. Management strategies in acute lymphoblastic leukemia. Oncology (Williston Park). 2011 Apr 15;25(4):328-35. Review. Erratum in: Oncology (Williston Park). 2011 May;25(6):551. PubMed PMID: 21618954. 2: Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011 Jun;16(3):274-80. doi: 10.1097/MOT.0b013e3283465715. Review. PubMed PMID: 21467936; PubMed Central PMCID: PMC3167800. 3: Margolin JF. Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians. Eur J Pediatr. 2011 Apr;170(4):419-25. doi: 10.1007/s00431-011-1424-7. Epub 2011 Feb 25. Review. PubMed PMID: 21350806. 4: Hockenberry MJ, McCarthy K, Taylor O, Scarberry M, Franklin Q, Louis CU, Torres L. Managing painful procedures in children with cancer. J Pediatr Hematol Oncol. 2011 Mar;33(2):119-27. doi: 10.1097/MPH.0b013e3181f46a65. Review. PubMed PMID: 21285907. 5: Horton TM, Berg SL. Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr. 2011 May;170(5):555-9. doi: 10.1007/s00431-010-1374-5. Epub 2010 Dec 30. Review. PubMed PMID: 21190039. 6: Metelitsa LS. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol. 2011 Aug;140(2):119-29. doi: 10.1016/j.clim.2010.10.005. Epub 2010 Nov 20. Review. PubMed PMID: 21095162; PubMed Central PMCID: PMC3444285. 7: Mueller BU. Hydroxyurea for children with sickle cell disease: are we starting too late? Pediatr Blood Cancer. 2011 Jan;56(1):3-4. doi: 10.1002/pbc.22858. Review. PubMed PMID: 21058289. 8: Venkateswaran L, Yee DL. Rare bleeding disorders in young women. J Pediatr Adolesc Gynecol. 2010 Dec;23(6 Suppl):S38-42. doi: 10.1016/j.jpag.2010.08.011. Review. PubMed PMID: 20934892. 9: Okur FV, Krance R. Stem cell transplantation in childhood non-Hodgkin's lymphomas. Curr Hematol Malig Rep. 2010 Oct;5(4):192-9. doi: 10.1007/s11899-010-0059-5. Review. PubMed PMID: 20661786. 10: Huye LE, Dotti G. Designing T cells for cancer immunotherapy. Discov Med. 2010 Apr;9(47):297-303. Review. PubMed PMID: 20423673; PubMed Central PMCID: PMC2931319. 11: Lau CC. Molecular classification of osteosarcoma. Cancer Treat Res. 2009;152:459-65. doi: 10.1007/978-1-4419-0284-9_26. Review. PubMed PMID: 20213408. 12: Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2010 Mar;10(3):337-51. doi: 10.1517/14712590903456003. Review. PubMed PMID: 20132056; PubMed Central PMCID: PMC2818535. 13: Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA; ALLNA 2008 Conference. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8. doi: 10.1002/pbc.22414. PubMed PMID: 20127846; PubMed Central PMCID: PMC2857540. 14: Pappo AS, Janeway KA. Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009 Feb;23(1):15-34, vii. doi: 10.1016/j.hoc.2008.11.005. Review. PubMed PMID: 19248968. 15: Louis CU, Brenner MK. Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. Curr Pharm Des. 2009;15(4):424-9. Review. PubMed PMID: 19199969; PubMed Central PMCID: PMC4122212. 16: Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist. 2009 Feb;14(2):164-73. doi: 10.1634/theoncologist.2008-0217. Epub 2009 Jan 28. Review. PubMed PMID: 19176633; PubMed Central PMCID: PMC2761094. 17: Berg SL. When too much is just enough: what do oncologists tell parents? Pediatr Blood Cancer. 2009 Apr;52(4):437-8. doi: 10.1002/pbc.21871. Review. PubMed PMID: 19058206. 18: Leen AM, Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol. 2008 Oct;143(2):169-79. doi: 10.1111/j.1365-2141.2008.07316.x. Epub 2008 Aug 7. Review. PubMed PMID: 18691164; PubMed Central PMCID: PMC3153888. 19: Rodgers C, Walsh T. Nutritional issues in adolescents after bone marrow transplant: a literature review. J Pediatr Oncol Nurs. 2008 Sep-Oct;25(5):254-64. doi: 10.1177/1043454208321115. Epub 2008 Jul 22. Review. PubMed PMID: 18648090. 20: Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R. Retinoblastoma: review of current management. Oncologist. 2007 Oct;12(10):1237-46. Review. PubMed PMID: 17962617.